AOTMiT: The Transparency Council will evaluate drugs for lung cancer, cervical cancer and plasmocytic myeloma, among others.

The agenda includes:

1 Prepare a position paper on the evaluation of the drug Talvey (talquetamabum) under drug program B.54. "Treatment of patients with plasmocytic myeloma" (ICD-10: C90.0).

2 Prepare a position paper on the evaluation of the drug Libtayo (cemiplimabum) under the drug program B.6. "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)".

3 Prepare a position paper on the evaluation of the drug Libtayo (cemiplimabum) under drug program B.159. "Treatment of patients with cervical cancer (ICD-10: C53)".

4 Prepare a position paper on the evaluation of the drug Tavneos (avacopanum) under drug program B.75. "Treatment of patients with active granulomatosis with vasculitis (GPA) or microscopic vasculitis (MPA) (ICD-10: M31.3, M31.8)".

5 Prepare a position paper to examine the appropriateness of issuing reimbursement approvals for medicinal products: XMTVI Maxamum for the indication: methylmalonic/propionic aciduria in pediatric patients aged 8 years and older and adults, including pregnant women; XMTVI Maxamaid for the indication: methylmalonic/propionic aciduria in infants and young children.

6 Prepare a position paper on the examination of the legitimacy of issuing approvals for reimbursement of the medicinal product Trandate (labetalol) for the indication: hypertension in pregnant women.

7 Prepare an opinion on the draft health policy program of the local government unit "Health policy program for the prevention of overweight and obesity in children from the Lodz region".

8 Prepare an opinion on changing the reimbursement availability category for the active substance pomalidomide - from drug program B.54. "Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)" to the chemotherapy catalog.

9 Prepare an opinion on the reimbursement of the active substance pomalidomide for the off-label indication: plasmocytic myeloma (ICD-10: C90.0) for: - treatment in combination with cyclophosphamide and dexamethasone of adult patients with plasmocytic myeloma who have previously received at least one line of treatment, including that containing lenalidomide, - treatment in combination with dexamethasone of adult patients with plasmocytic myeloma who have previously received at least one line of treatment, including that containing lenalidomide, as part of the chemotherapy catalog for the indication defined by the clinical condition.

10.Preparation of an opinion on reimbursement of the active substance amlodipinum in the indication: Raynaud's sign associated with systemic scleroderma - first-line treatment.

11.Preparing an opinion on the reimbursement of the active substance nitrendipinum in the indication: Raynaud's sign associated with systemic scleroderma - first-line treatment.

12.Preparation of an opinion on the reimbursement of the active substance clofarabinum for the indications: - Langerhans cell histiocytosis not elsewhere classified - in the third line of treatment (ICD-10: D76.0); - acute myeloid leukemia - in children and adolescents up to the age of 18 years diagnosed with primary refractory acute myeloid leukemia or its first relapse refractory to second-line therapy, and in children and adolescents up to the age of 18 years diagnosed with second relapse acute myeloid leukemia (ICD-10: C92.0).

13.Preparation of an opinion on reimbursement of the active substance romiplostim for the indication: diagnosis of persistent, understood as lasting more than 6 months, primary immune thrombocytopenia (ITP), under the proposed drug program: B.98 "Treatment of pediatric patients with chronic primary immune thrombocytopenia (ICD-10 D69.3)".

Source: AOTMiT